Digene works with FDA on HPV (Human Papilloma Virus) test, expects "yes" by 2003:
This article was originally published in Clinica
Executive Summary
Apparently unfazed by the restrictive provisions attached to the US approval of its HPV DNA Pap test as a primary screen for cervical cancer, the Gaithersburg, Maryland company says it will supply more data, as requested by the FDA. It expects an unconditional approval for the product before the end of next year. Last month, the FDA's microbiology devices panel voted 6-2 in favour of approving the company's Hybrid Capture 2 High-Risk HPV DNA test, but with enough conditions to remove all the gloss from the decision.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.